What is the interaction between Phenytoin and Tacrolimus (immunosuppressant)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Phenytoin and tacrolimus can interact significantly, requiring careful monitoring and potential dose adjustments, as phenytoin can decrease tacrolimus blood levels by inducing CYP3A4 enzymes, which metabolize tacrolimus, and this interaction may lead to subtherapeutic tacrolimus levels and increased risk of transplant rejection in patients taking tacrolimus for immunosuppression. When these medications are used together, the tacrolimus dose may need to be increased by 25-50% with close monitoring of blood levels, as suggested by the general principles of drug interactions 1. If phenytoin is discontinued in a patient on tacrolimus, the tacrolimus levels may rise, potentially causing toxicity, so the tacrolimus dose may need to be reduced. Blood level monitoring for both medications is essential, with tacrolimus trough levels checked 3-5 days after any change in phenytoin therapy. Additionally, patients should be monitored for signs of tacrolimus toxicity (tremor, headache, nephrotoxicity) or efficacy issues. Some key points to consider when managing this interaction include:

  • The mechanism of interaction: phenytoin induces CYP3A4, which metabolizes tacrolimus, leading to decreased tacrolimus levels
  • The potential consequences of the interaction: subtherapeutic tacrolimus levels, increased risk of transplant rejection
  • The management of the interaction: close monitoring of blood levels, potential dose adjustments of tacrolimus
  • The consideration of alternative anticonvulsants with fewer interactions, such as levetiracetam or lamotrigine, if appropriate for the patient's seizure type. It is also important to note that the evidence from the provided studies does not directly address the interaction between phenytoin and tacrolimus, but the general principles of drug interactions and the metabolism of tacrolimus by CYP3A4 enzymes, as described in 1, support the need for careful monitoring and potential dose adjustments when these medications are used together.

From the Research

Phenytoin and Tacrolimus Interaction

  • The interaction between phenytoin and tacrolimus is significant due to the effect of phenytoin on the cytochrome P-450 3A4 isoenzyme, which is responsible for the metabolism of tacrolimus 2.
  • Phenytoin can induce the metabolism of tacrolimus, leading to decreased tacrolimus levels 3, 4.
  • This interaction can be utilized to manage supratherapeutic tacrolimus levels, particularly in cases where tacrolimus toxicity occurs due to drug-drug interactions with other medications such as nirmatrelvir/ritonavir 5, 6.

Management of Tacrolimus Toxicity with Phenytoin

  • Phenytoin has been used as a treatment option to decrease tacrolimus concentrations in patients with acute, symptomatic tacrolimus toxicity 4.
  • The use of phenytoin to induce the metabolism of tacrolimus has been shown to be effective in reducing tacrolimus levels and alleviating symptoms of toxicity 5, 4, 6.
  • The dosage and duration of phenytoin treatment may vary depending on the individual case and the severity of the toxicity 5, 4.

Drug-Drug Interactions with Nirmatrelvir/Ritonavir

  • The combination of nirmatrelvir/ritonavir with tacrolimus can lead to significant drug-drug interactions, resulting in supratherapeutic tacrolimus levels and potential toxicity 5, 6.
  • The use of phenytoin as a CYP3A4 inducer can help manage these interactions and reduce the risk of tacrolimus toxicity 5, 6.
  • Close monitoring of tacrolimus levels and adjustment of the immunosuppressive regimen may be necessary when using nirmatrelvir/ritonavir in patients taking tacrolimus 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tacrolimus: a new immunosuppressive agent.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1995

Research

Drug interactions between tacrolimus and phenytoin in Japanese heart transplant recipients: 2 case reports.

International journal of clinical pharmacology and therapeutics, 2007

Research

Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2024

Research

Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.